ASH-HSANZ Abstract Achievement Award

The following individuals received the ASH-HSANZ Abstract Achievement Award, which is part of the National Partner Society Abstract Achievement Awards program.

2025

Michael Ashby
Australian Centre for Blood Diseases, Monash University
Relapse associated aberrant DNA hypermethylation in AML post-allogeneic stem cell transplantation

2024

Adrian Minson, MBBS
University of Melbourne
A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics

2023

James Kuzich, MBBS, FRACP, FRCPA
Peter MacCallum Cancer Centre, Australia
A Rare Cell State Underpins Diverse Mechanisms of Adaptive Resistance to CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

2022

Chanukya Colonne, BSc(Adv), MBBS, PhD
University of Sydney
A Putative Erythroid Synapse Linking Developing Erythroblasts and Macrophages in Erythroblastic Islands

2021

Katharine Lewis, BMBS, FRCPath, MRCPath
Sir Charles Gairdner Hospital Perth
High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients
Abstract #181

2020

Naranie Shanmuganathan, FRACP, FRCPA, MBBS
Royal Adelaide Hospital and SA Pathology
Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes
Abstract #49

2019

Chong Chyn Chua, MBBS, FRACP, FRCPA
The Alfred Hospital and Monash University
Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study
Abstract #462

2018 Recipient

Naranie Shanmuganathan, MBBS
Royal Adelaide Hospital and SA Pathology
The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort
Abstract #1731

2017 Recipient

Joshua Tobin, MD
Princess Alexandra Hospital
The Tumor Microenvironment Is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma
Abstract #728